C. Krieckaert

THU0205 The effect of certolizumab drug concentration and anti-drug antibodies on tnf neutralisation

M. Nurmohamed, G. Wolbink, M. Hart, 2018, Clinical and experimental rheumatology.

Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study.

B. Dijkmans, W. Lems, C. Wijbrandts, 2011, Arthritis and rheumatism.

Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study

W. Lems, M. Boers, C. Wijbrandts, 2022, RMD Open.

Serum drug concentrations to optimize switching from adalimumab to etanercept in rheumatoid arthritis

T. Rispens, R. van Vollenhoven, M. Nurmohamed, 2019, Scandinavian journal of rheumatology.

Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial

M. Boers, M. Nurmohamed, T. Rispens, 2022, Scandinavian journal of rheumatology.

Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up

G. Wolbink, M. Nurmohamed, T. Rispens, 2013, Annals of the rheumatic diseases.